文献速递造血干细胞移植与细胞治疗

使用年长同胞相合供者与年轻替代供者的移植结局比较:一项CIBMTR分析

Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis.
PubMed 文献 · Blood Adv · 2025-01-01

该研究比较了≥50岁受者接受≥50岁HLA相合同胞供者(MSD)与≤35岁年轻替代供者(MUD、单倍体、MMUD)的allo-HCT结局,按PTCy或CNI预防GVHD分组。PTCy组中MSD与其他供者类型5年OS相似;年轻MUD与改善的DFS相关。

要点

  • PTCy预防下,MSD与MUD、单倍体、MMUD的5年OS相似。
  • 与MSD相比,MUD在PTCy和CNI预防下均与改善的DFS相关。
  • PTCy下,单倍体供者与较MUD更差的OS相关。

核心结论

  • 年长MSD与年轻替代供者产生相似的OS;然而,使用年轻MUD与年长受者改善的DFS相关。

研究设计与样本

  • 回顾性分析2014年至2021年间报告至国际血液与骨髓移植研究中心(CIBMTR)的allo-HCT病例。
  • 纳入≥50岁受者,供者包括≥50岁MSD、≤35岁MUD、单倍体相关供者和MMUD。
  • 按PTCy或CNI为基础的GVHD预防分组,主要终点为OS。
  • 共纳入14662例HCT受者,其中3746例接受PTCy预防,10916例接受CNI预防。

主要发现

  • PTCy组中,MSD后5年OS为44%,MUD后为52%(HR 1.20;95%CI 1.03-1.41;P=0.09),单倍体后为45%(HR 1.02;95%CI 0.88-1.18;P=1.00),MMUD后为46%(HR 1.00;95%CI 0.83-1.21;P=1.00)。
  • 与MSD相比,MUD在PTCy预防下与改善的DFS相关(HR 1.21;95%CI 1.05-1.40;P=0.048),在CNI预防下亦相关(HR 1.09;95%CI 1.04-1.15;P<0.01)。
  • PTCy下,单倍体供者与较MUD更差的OS相关(HR 1.18;95%CI 1.05-1.33;P=0.04)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Whether older HLA-matched sibling donors (MSD) are preferred over younger alternative donors for allogeneic hematopoietic cell transplantation (allo-HCT) with posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis is unclear. We compared outcomes in allo-HCT recipients ≥50 years old after HCT from an older MSD (≥50 years) with recipients of younger (≤35 years) HLA-matched unrelated donor (MUD), haploidentical related donor (haplo), and HLA-mismatched unrelated donor (MMUD), grouped based on PTCy or calcineurin-inhibitor (CNI) based GVHD prophylaxis, that were reported to the Center for International Blood and Marrow Transplant Research between 2014 and 2021. The primary end point was overall survival (OS). Among 14 662 HCT recipients, 3746 received PTCy- and 10 916 CNI-based prophylaxis. In patients receiving PTCy-based HCT, the adjusted 5-year OS was similar between MSD and other donor types: 44% after MSD versus 52% after MUD (multivariable hazard ratio [HR]: 1.20; 95% confidence interval [CI], 1.03-1.41; P = .09), 45% after haplo donor (HR, 1.02; 95% CI, 0.88-1.18; P = 1.00), and 46% after MMUD (HR, 1.00; 95% CI, 0.83-1.21; P = 1.00). Compared with MSD, use of MUD associated with improved disease-free survival (DFS) with PTCy-based (HR, 1.21; 95% CI, 1.05-1.40; P = .048) and CNI-based (HR, 1.09; 95% CI, 1.04-1.15; P < .01) prophylaxis. Haplo donor use associated with worse OS compared with MUD use with PTCy (HR, 1.18; 95% CI, 1.05-1.33; P = .04). Older MSDs result in similar OS compared with younger alternative donors; however, use of a younger MUD associated with improved DFS in older-aged recipients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Nath K, Zhang MJ, Bye M, et al. Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis. Blood Adv. 2025. PMID: 40048743. doi:10.1182/bloodadvances.2024014858

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。